This post-hoc analysis evaluated candidate biomarkers of long-term efficacy of subcutaneous interferon beta-1a (sc IFN β-1a) in REFLEX/REFLEXION studies of clinically isolated syndrome. Samples from 507 REFLEX and 287 REFLEXION study participants were analyzed. All investigated biomarkers were significantly upregulated 1.5–4-fold in response to sc IFN β-1a treatment versus baseline (p ≤ 0.008). The validity of MX1, 2’5’OAS, and IL-1RA as biomarkers of response to sc IFN β-1a was confirmed in this large patient cohort, with biomarkers consistently upregulated in a dose-dependent manner. Neopterin, TRAIL, and IP-10 were confirmed as biomarkers associated with long-term sc IFN β-1a treatment efficacy over 5 years.

这项事后分析评估了在临床孤立综合征的 REFLEX/REFLEXION 研究中皮下干扰素 β-1a (sc IFN β-1a) 长期疗效的候选生物标志物。分析了来自 507 名 REFLEX 和 287 名 REFLEXION 研究参与者的样本。与基线相比，所有研究的生物标志物都显着上调了 1.5-4 倍，以响应 sc IFN β-1a 治疗（p  ≤ 0.008）。的有效性MX1，2'5'OAS，和IL-1RA作为响应于皮下IFNβ-1a的生物标志物被证实在这个大的患者群体，与生物标记物以剂量依赖的方式一致地上调。Neopterin、TRAIL 和 IP-10 被确认为与 5 年以上长期 sc IFN β-1a 治疗效果相关的生物标志物。